Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease

NCT05797597 is registered in ClinicalTrials.gov with Lucyna Mastalerz as lead sponsor.

NCT NCT05797597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05797597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease
Lead sponsor
Lucyna Mastalerz
Phase
Phase 3
Overall status
Unknown status
Start date
December 7, 2022
Completion date
February 28, 2025
Enrollment
76 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aerd - aspirin exacerbated respiratory disease